The company completed enrollment in the LORIKEET Phase 2 trial for lorigerlimab, targeting metastatic castration-resistant ...
ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACTDevelopment of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback